Motesanib (AMG-706)
分子式: C22H23N5O分子量:373.45
简介: Motesanib (AMG-706)是一种具有口服生物活性的受体酪氨酸激酶 (receptor tyrosine kinase)抑制剂,对VEGFR1, VEGFR2, VEGFR3, Kit, PDGFR和Ret的IC50值分别为2、3、6、8、84和59 nM。
物理性状及指标:
外观:……………………粉末
溶解性:…………………H2O :Insoluble;Ethanol:8 mg/mL (21.42 mM);DMSO: 75 mg/mL (200.83 mM)
含量:……………………>98%
储存温度:-20℃,避光防潮密闭干燥
运输条件:2~8℃运输
生物活性
描述
|
Motesanib (AMG-706)是一种具有口服生物活性的受体酪氨酸激酶 (receptor tyrosine kinase)抑制剂,对VEGFR1, VEGFR2, VEGFR3, Kit, PDGFR和Ret的IC50值分别为2、3、6、8、84和59 nM。 |
|||||||||||
IC50 & Target |
|
|||||||||||
体外 |
Motesanib has broad activity against the human VEGFR family, and displays > 1000 selectivity against EGFR, Src, and p38 kinase. Motesanib significantly inhibits VEGF-induced cellular proliferation of HUVECs with an IC50 of 10 nM, while displaying little effect at bFGF-induced proliferation with an IC50 of >3,000 nM. Motesanib also potently inhibits PDGF-induced proliferation and SCF-induced c-kit phosphorylation with IC50 of 207 nM and 37 nM, respectively, but not effective against the EGF-induced EGFR phosphorylation and cell viability of A431 cells Althouth displaying little antiproliferative activity on cell growth of HUVECs alone, Motesanib treatment significantly sensitizes the cells to fractionated radiation. |
|||||||||||
体内 |
Motesanib (100 mg/kg) significantly inhibits VEGF-induced vascular permeability in a time-dependent manner. Oral administration of Motesanib twice daily or once daily potently inhibits, in a dose-dependent manner, VEGF-induced angiogenesis using the rat corneal model with ED50 of 2.1 mg/kg and 4.9 mg/kg, respectively. Motesanib induces a dose-dependent tumor regression of established A431 xenografts by selectively targeting neovascularization in tumor cells. Motesanib in combination with radiation displays significant anti-tumor activity in head and neck squamous cell carcinoma (HNSCC) xenograft models. Motesanib treatment also induces significant dose-dependent reductions in tumor growth and blood vessel density of MCF-7, MDA-MB-231, or Cal-51 xenografts, which can be markedly enhanced when combined with docetaxel or tamoxifen |
相关产品推荐 (更多相关靶点抑制剂请详询官网或客服)
MB1050
|
西地尼布;AZD2171 |
MB1226 |
Sorafenib tosylate |
MB1230 |
Sunitinib Malate |
储液配置及储存: 按表中溶解性配置;如溶解困难,可以通过快速搅拌,超声或温和加热(在45-60°C下水浴)。液体稳定性报道的很少,建议现配现用,如需储存,建议:-20℃1-3月;-80℃ 3-6月。
1 mg |
5 mg |
10 mg |
|
1 mM |
2.6777 mL |
13.3887 mL |
26.7773 mL |
5 mM |
0.5355 mL |
2.6777 mL |
5.3555 mL |
10 mM |
0.2678 mL |
1.3389 mL |
2.6777 mL |
50 mM |
0.0536 mL |
0.2678 mL |
0.5355 mL |
【注意 】
●我司产品为非无菌包装,若用于细胞培养,请提前做预处理,除去热原细菌,否则会导致染菌。
●部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,以上数据仅供参考交流研究之用。
我司所售出产品仅供于科研研究用途(非临床科研研究),每次销售产品行为都适用于我司网上所列明的。